Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 10/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 10/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 10/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 8/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 8/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533266 | 0.94 | KCNH2 (0.42) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL25239780 | 0.87 | TSHR (0.37) | KCNH2HRH3TSHR | |
| SCHEMBL18215382 | 0.81 | TSHR (0.54) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL28416 | 0.81 | TSHR (0.54) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18388973 | 0.81 | TSHR (0.54) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL19662088 | 0.80 | KCNH2 (0.50) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1266842 | 0.79 | TSHR (0.52) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL28785738 | 0.78 | KCNH2 (0.35) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL12541860 | 0.78 | KCNH2 (0.46) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21422741 | 0.78 | KCNH2 (0.46) | KCNH2HRH3PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397638-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Merial, Inc. (US) | 2018-11-07 | — | — | EP | claimed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | claimed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-108699052-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10344056-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3397638-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Merial, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-5190958-A | Fungicides | SHELL RESEARCH LIMITED (GB) | 1993-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344056-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | KCNH2 2849/4885HRH3 1321/4885PRKAG1 1706/4885 |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | KCNH2 3777/4885HRH3 1074/4885PRKAG1 1503/4885 |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | KCNH2 2849/4885HRH3 1321/4885PRKAG1 1706/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KCNH2 1300/4885HRH3 100/4885PRKAG1 755/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | KCNH2 2849/4885HRH3 1321/4885PRKAG1 1706/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KCNH2 1354/4885HRH3 107/4885PRKAG1 647/4885 |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | KCNH2 2849/4885HRH3 1321/4885PRKAG1 1706/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | KCNH2 211/4885HRH3 579/4885PRKAG1 3699/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | KCNH2 2849/4885HRH3 1321/4885PRKAG1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.